Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA hits pause on reviewing Moderna COVID-19 vaccine for adolescents 

The agency is concerned about the rare risk of myocarditis linked to mRNA vaccines in 12-to-17-year-olds.

By Brian Buntz | October 18, 2021

ModernaThe FDA will postpone considering whether to extend emergency use authorization of Moderna’s (NSDQ:MRNA) COVID-19 vaccine over myocarditis concerns.

Some regulators have concluded that the risk of myocarditis is higher in recipients of the Moderna vaccine than the Pfizer-BioNTech vaccine.

Japan recently authorized men 30 and under who received an initial dose of the Moderna vaccine to receive a second dose of the Pfizer-BioNTech vaccine. Japanese authorities also recommended requiring a four-week interval between the first and second doses in this subpopulation — the same as the 28-day interval Moderna recommended for the second dose.

Sweden, Denmark, Norway and Finland recently recommended that younger age groups avoid obtaining the Moderna COVID-19 vaccine until further notice.

Health authorities in Europe are scrutinizing data to determine whether the Moderna vaccine increases the risk of myocarditis in younger recipients.

FDA data concerning the Moderna and Pfizer-BioNTech vaccines don’t reflect significant differences in myocarditis rates, Moderna Chief Medical Officer Paul Burton told WSJ.

Cases of myocarditis associated with mRNA vaccines tend to be minor and short in duration, although some vaccine recipients have been hospitalized over the condition.

In any event, the risk of contracting myocarditis is higher for those with COVID-19 infections than COVID-19 vaccine recipients.

The Moderna vaccine contains 100 micrograms of mRNA, which could increase short-term adverse effects while also providing a more durable immune response.

Moderna plans on recommending a 50 microgram dose level in its boosters.

In mid-day trading, MRNA shares were up 2.84% apiece to $333.41.


Filed Under: Infectious Disease
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, COVID-19 vaccines, Moderna
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government
Icosavax
Icosavax shares positive early results for VLP vaccine candidate against RSV

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50